Secretory Phospholipase A2-IIA and Cardiovascular Disease: A Mendelian Randomization Study.

Identificador:  PC:515

Handle: https://hdl.handle.net/20.500.11797/PC515

Autores:  Holmes, M.V.; Simon, T.; Exeter, H.J; Folkersen, L.; Asselbergs, F.W.; Guardiola, M.; Cooper, J.A.; Palmen, J.; Hubacek, J.A.; Carruthers, K.F.; Horne, B.D.; Brunisholz, K.D.; Mega, J.L.; Van Iperen, E.P.; Li, M.; Leusink, M.; Trompet, S.; Verschuren, J.J.; Hovingh, G.K.; Dehghan, A.; Nelson, C.P.; Kotti, S.; Danchin, N.; Scholz, M.; Haase, C.L.; Rothenbacher, D.; Swerdlow, D.I.; Kuchenbaecker, K.B.; Staines-Urias, E.; Goel, A.; Van 't Hooft, F.; Gertow, K.; De Faire, U.; Panayiotou, A.G.; Tremoli, E., Baldassarre, D.; Veglia, F.; Holdt, L.M.; Beutner, F.; Gansevoort. R.T.; Navis, G.J.; Mateo, L.I.; Breitling, L.P.; Brenner, H.; Thiery, J.; Dallmeier, D.; Franco-Cereceda, A.; Boer, J.M.; Stephens, J.W.; Hofker, M.H.; Tedgui, A.; Hofman, A.; Uitterlinden, A.G.; Adamkova, V.; Pitha, J.; Onland-Moret, N.C.; Cramer, M.J.; Nathoe, H.M.; Spiering, W.; Klungel, O.H.; Kumari, M.; Whincup, P.H.; Morrow, D.A.; Braund, P.S.; Hall, A.S.; Olsson, A.G.; Doevendans, P.A.; Trip, M.D.; Tobin, M.D.; Hamsten, A.; Watkins, H.; Koenig, W.; Nicolaides, A.N.; Teupser, D.; Day, I.N.; Carlquist, J.F.; Gaunt, T.R.; Ford, I.; Sattar, N.; Tsimikas, S.; Schwartz, G.G.; Lawlor, D.A.; Morris, R.W.; Sandhu, M.S.; Poledne, R.; Maitland-van der Zee, A.H.; Khaw, K.T.; Keating, B.J.; Van der Harst, P.; Price, J.F.; Mehta, S.R.; Yusuf, S.; Witteman, J.C.; Franco, O.H.; Jukema, J.W.; De Knijff, P.; Tybjaerg-Hansen, A.; Rader, D.J.; Farrall, M.; Samani, N.J.; Kivimaki, M.; Fox, K.A.; Humphries, S.E.; Anderson, J.L.; Boekholdt, S.M.; Palmer, T.M.; Eriksson, P.; Paré, G.; Hingorani, A.D.; Sabatine, M.S.; Mallat, Z.; Casas, J.P.; Talmud, P.J.

Resumen:
This study sought to investigate the role of secretory phospholipase A2(sPLA2)-IIA in cardiovascular disease. Higher circulating levels of sPLA2-IIA mass or sPLA2enzyme activity have been associated with increased risk ofcardiovascular events. However, it is not clear if this association is causal. A recent phase III clinical trial of an sPLA2inhibitor (varespladib) was stopped prematurely for lack of efficacy